Autres langues Xenon Pharmaceuticals Inc.

Actions

XENE

CA98420N1050

Marché Fermé - Nasdaq Autres places de cotation 22:30:01 06/05/2024			Varia. 5j.	Varia. 1 janv.
43,19 ^USD	-1,28%		+1,08%	-6,23%

19/04	Xenon Pharmaceuticals Inc. annonce la démission de membres de son conseil d'administration	CI
11/03	Transcript : Xenon Pharmaceuticals Inc. Presents at Leerink Partners Global Biopharma Conference 2024, Mar-11-2024 11:20 AM

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Corporate Update	02/05
Xenon Pharmaceuticals Inc. Announces Board Resignations	19/04
Xenon Pharmaceuticals Showcases XEN1101 at the American Academy of Neurology 2024 Annual Meeting	16/04
Xenon Pharmaceuticals to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference	10/04
Xenon Pharmaceuticals to Present at the 23rd Annual Needham Virtual Healthcare Conference	04/04
Xenon Pharmaceuticals to Present at Stifel 2024 Virtual CNS Days	12/03
Xenon Pharmaceuticals to Present at Stifel 2024 Virtual CNS Days	12/03
Xenon Pharmaceuticals Insider Sold Shares Worth $330,290, According to a Recent SEC Filing	08/03
Xenon Pharmaceuticals Insider Sold Shares Worth $601,615, According to a Recent SEC Filing	08/03
Xenon Pharmaceuticals : Alberta Securities Commission British Columbia Securities Commission Ontario Securities Commission - Form 8-K	08/03
Xenon Pharmaceuticals to Present at Leerink Partners Global Biopharma Conference 2024	05/03
Xenon Pharmaceuticals to Present at Leerink Partners Global Biopharma Conference 2024	05/03
Xenon Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/02
Xenon Pharmaceuticals Q4 Net Loss Widens	29/02
Xenon Pharmaceuticals: Q4 Earnings Snapshot	29/02
Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update	29/02
Xenon Pharmaceuticals Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	29/02
Certain Common Shares of Xenon Pharmaceuticals Inc. are subject to a Lock-Up Agreement Ending on 27-FEB-2024.	27/02
Certain Warrants of Xenon Pharmaceuticals Inc. are subject to a Lock-Up Agreement Ending on 27-FEB-2024.	27/02
Certain Options of Xenon Pharmaceuticals Inc. are subject to a Lock-Up Agreement Ending on 27-FEB-2024.	27/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Xenon Pharmaceuticals Inc.

Actions

XENE

CA98420N1050

Autres langues

Filtres